Biogen
BIIB
954 hedge funds and large institutions have $28B invested in Biogen in 2024 Q1 according to their latest regulatory filings, with 104 funds opening new positions, 304 increasing their positions, 355 reducing their positions, and 144 closing their positions.
0% more call options, than puts
Call options by funds: $303M | Put options by funds: $303M
0.66% less ownership
Funds ownership: 89.92% → 89.26% (-0.66%)
5% less funds holding
Funds holding: 1,002 → 954 (-48)
14% less repeat investments, than reductions
Existing positions increased: 304 | Existing positions reduced: 355
17% less capital invested
Capital invested by funds: $33.7B → $28B (-$5.74B)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
28% less first-time investments, than exits
New positions opened: 104 | Existing positions closed: 144
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$507M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$140M |
| 3 |
BGC
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
+$134M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$93.7M |
| 5 |
VanEck Associates
New York
|
+$74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$341M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$151M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
-$93.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$89.1M |
| 5 |
JP Morgan Chase
New York
|
-$82.6M |
BIIB Hedge Fund Activity: Q1 2024 in Review
954 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2024, worth a combined $28B — down 17% from $33.7B a quarter earlier.
Sellers outnumbered buyers: 144 funds closed out of BIIB and 104 opened new positions — a net loss of 40 holders — while 355 trimmed existing stakes and 304 added.
The largest buyer was Vanguard Group, adding an estimated $507M. The largest seller was Morgan Stanley, cutting an estimated $341M.
- 954 institutional investors held Biogen (BIIB) as of Q1 2024, down from 1,002 in Q4 2023.
- Funds reported $28B of Biogen stock for Q1 2024, down 17% quarter-over-quarter.
- 104 funds opened new Biogen positions in Q1 2024 and 144 closed out, a net change of -40 holders.
- The largest Biogen buyer in Q1 2024 was Vanguard Group, an estimated $507M added.
- The largest Biogen seller in Q1 2024 was Morgan Stanley, an estimated $341M sold.
Based on aggregated 13F filings for Q1 2024.